Anti-Infectives Rx
Date: Location: Cost:
September 19, 2017 Harvard Medical School - Joseph B. Martin Conference Center
77 Avenue Louis Pasteur
Boston, MA 02115
Location >

Starting at $1950


Dress Code:
Business Attire




Time Agenda
7:30-8:30 am

Registration and Networking Breakfast

8:30-8:45 am

Welcome and Opening Remarks

8:45-9:15 am

Tackling Resistance: The Promise and The Challenge
Eliav BarrVP & Head, Infectious Disease Late Stage Development, Merck; Nicholas BenedictCEO, Allecra Therapeutics; Cara Cassino, CMO, ContraFect; Ryan Davies, CEO, Curza; Evan JonesChairman & CEO, OpGen; Jeff Riley, CEO, Synthetic Biologics

9:15-9:45 am

Fostering Innovation via Partnerships and Deals
Martin Driscoll, CEO, Spring Bank Pharmaceuticals; Charlotte HubbertPartner, Bill & Melinda Gates Foundation; Robert NelsenManaging Director, ARCH Venture Partners; Laurence ReidCEO, Warp Drive Bio; Frederick Sweeney, VP BD & Strategic Aliances, bioMerieux

9:45-10:05 am

Fireside Chat

10:05-10:30 am

Networking Break

10:30-11:00 am

Innovation versus Pricing: Maintaining Cost Efficacy for Treatments
Will Lewis
, CEO, Insmed

11:00-11:30 am

Progress Towards Curative Therapies
James Sapirstein
, CEO, Contravir Pharmaceuticals

11:30-12:00 pm

Collaboration with Diagnostics

12:00-1:00 pm

Networking Lunch

1:00-1:30 pm

Regulatory Challenges: Expanding Endpoints
Anil Diwan, President & Chairman, NanoViricides; David MantusCDO, Arsanis; Antony Pfaffle, CSO, CorMedix
Moderator: Marco TagliettiCEO, Scynexis

1:30-2:00 pm

Enhancing Treatment in Emerging Markets 
Shalabh Gupta
, President & CEO, Globavir 

2:00-2:30 pm

Advances Against Rare and Resistant Pathogens
Gregory Mario, President & CEO, Taxis Pharmaceuticals; Elizabeth PosillicoPresident & CEO, EluSys; Malcom Thomas, CEO, Agile Sciences; Jeff WagerCEO, EnBiotix; Zachary ZimmermanCEO, Forge Therapeutics

2:30-2:50 pm

Bench to Bedside Keynote
Rita Colwell
Former Director, National Science Foundation

2:50-3:20 pm

Networking Break

3:20-3:50 pm

The New Wave of Anti-Infectives: MicroBiome & Immunotherapy
Todd Black
, Executive Director of Infectious Diseases, Merck; Steven Gilman, Chairman, ContraFect; Lee JonesCEO, Rebiotix; Bernat Olle, CEO, Vedanta Biosciences; Shelley TrucksisCMO & EVP, Seres Therapeutics
Moderator: Kevin ForrestChief Strategy Officer, Cidara Therapeutics

3:50-4:20 pm

Breakthroughs in Infectious Disease Programs
Chip ClarkCEO & President, Genocea; David Huang, CMO, MotifBio; Roelof Rongen, CEO, Matinas Biopharma; Vu TruongCEO, Aridis
Moderator: Jeffrey MoorePresident, MP Healthcare

4:20-4:50 pm

Industry Outlook: The Next 5 Years
Rahul DhandaSVP, T2 Biosystems; Rasmus Toft-Kehler, CEO & Co-Founder, AntibioTx
Moderator: Jeff BaxterPresident and CEO, VBI Vaccines

4:50-6:00 pm

Cocktails and Hors d'oeuvres

Supporting Sponsors: (see all sponsors)